Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

BACKGROUND: The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin(® )ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal dialysis (PD) patients than conventional oral iron supplementation (Ferrogradu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barraclough, Katherine A, Noble, Euan, Leary, Diana, Brown, Fiona, Hawley, Carmel M, Campbell, Scott B, Isbel, Nicole M, Mudge, David W, van Eps, Carolyn L, Sturtevant, Joanna M, Johnson, David W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723098/
https://www.ncbi.nlm.nih.gov/pubmed/19635169
http://dx.doi.org/10.1186/1471-2369-10-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723098/
https://www.ncbi.nlm.nih.gov/pubmed/19635169
http://dx.doi.org/10.1186/1471-2369-10-20

Ejemplares similares